ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma | DNA RNA and Cells

ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma Details Category: DNA RNA and Cells Published on Monday, 29 August 2022 13:24 Hits: 84 First in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy Data showed potent anti-tumor activity …

ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma | DNA RNA and Cells Read More »